Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Interest Expenses (2022 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Interest Expenses for 4 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest Expenses rose 137.12% to $8.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.3 million, a 52.05% increase, with the full-year FY2025 number at $22.3 million, up 52.06% from a year prior.
  • Interest Expenses was $8.3 million for Q4 2025 at Madrigal Pharmaceuticals, up from $7.5 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $8.3 million in Q4 2025 to a low of $780000.0 in Q2 2022.
  • A 4-year average of $3.6 million and a median of $3.5 million in 2024 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: surged 271.92% in 2023, then dropped 14.1% in 2025.
  • Madrigal Pharmaceuticals' Interest Expenses stood at $1.7 million in 2022, then skyrocketed by 136.09% to $4.0 million in 2023, then fell by 11.89% to $3.5 million in 2024, then skyrocketed by 137.12% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Interest Expenses are $8.3 million (Q4 2025), $7.5 million (Q3 2025), and $3.3 million (Q2 2025).